Adam R. Craig

2018

In 2018, Adam R. Craig earned a total compensation of $3M as President, Chief Executive Officer and Interim Chief Medical Officer at CTI BioPharma, a 46% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$311,575
Option Awards$2,149,080
Salary$563,750
Other$8,250
Total$3,032,655

Craig received $2.1M in option awards, accounting for 71% of the total pay in 2018.

Craig also received $311.6K in non-equity incentive plan, $563.8K in salary and $8.3K in other compensation.

Rankings

In 2018, Adam R. Craig's compensation ranked 3,823rd out of 14,244 executives tracked by ExecPay. In other words, Craig earned more than 73.2% of executives.

ClassificationRankingPercentile
All
3,823
out of 14,244
73rd
Division
Manufacturing
1,412
out of 5,765
76th
Major group
Chemicals And Allied Products
502
out of 2,128
76th
Industry group
Drugs
419
out of 1,817
77th
Industry
Pharmaceutical Preparations
326
out of 1,391
77th
Source: SEC filing on April 4, 2019.

Craig's colleagues

We found three more compensation records of executives who worked with Adam R. Craig at CTI BioPharma in 2018.

2018

Jack Singer

CTI BioPharma

Chief Scientific Officer

2018

Bruce Seeley

CTI BioPharma

Chief Operating Officer

2018

David Kirske

CTI BioPharma

Chief Financial Officer

News

In-depth

You may also like